FDA Approves the First-Ever US Biosimilar

The US Food & Drug Administration has approved the country's first biosimilar product, a move observers say will open the door for lower cost, generic-like biological drugs.

The newly approved product sold as Zarxio, or Zarzio outside the US (filgrastim-sndz), was developed by Sandoz, the generics arm of Novartis, as a cheaper alternative to Amgen's Neupogen (filgrastim), a biologic drug prescribed to boost white blood cells in cancer patients.

In 2010, the US Congress paved the way for the FDA to approve the prescription of biological generics under a provision of the Affordable Care Act (known colloquially as Obamacare) in an attempt to boost competition.

The FDA's approval of Zarxio marks a significant milestone for the United States healthcare system and for patients who might suffer from neutropenia," said Carol Lynch, global head of Biopharmaceuticals & Oncology Injectables at Sandoz, which claims to be the largest producer of biosimilars.

To accelerate the launch of biosimilars, the FDA has developed a path to approval that requires companies to submit fewer clinical and preclinical data than for new biologics. At the same time, manufacturers must show that there are no "clinically meaningful" differences between these and a previously approved reference product for that indication.

Currently, the FDA is said to have at least four applications for biosimilars under review.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.